U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,129.66
    -65.84 (-0.27%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody.

  • The results will be presented at the American Society of Gene and Cell Therapy.

  • Data demonstrate durable expression in the central nervous system (CNS). They may represent a new single-dose therapeutic strategy for treating various tauopathies such as progressive supranuclear palsy, frontal, temporal dementia, and Alzheimer's disease.

  • Voyager has developed modular antibody vectorization cassettes consisting of an adeno-associated virus (AAV) vector and a transgene encoding anti-tau monoclonal full-length antibodies.

  • Following intravenous administration and transduction of target cells in the brain, the expressed antibodies are functionally reconstituted and subsequentially secreted into the parenchyma.

  • Anti-tau antibody expression was detected as early as two days post-dose, reaching maximum levels at day 7, with durable expression extending to 28 days.

  • Dose-dependent decreases in the levels of pathological tau and neurofibrillary tangles were observed, resulting in up to 59% reduction in tau pathology.

  • Price Action: VYGR shares are trading 2.5% higher at $4.51 on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.